Saleh Ablaa S, Abdel-Gabbar Mohammed, Gabr Hala, Shams Anwar, Tamur Shadi, Mahdi Emad A, Ahmed Osama M
Department of Biochemistry, Faculty of Science, Beni-Suef University Beni-Suef 62521, Egypt.
Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University Cairo 11435, Egypt.
Am J Transl Res. 2024 Jul 15;16(7):2793-2813. doi: 10.62347/FGHV2647. eCollection 2024.
Osteoarthritis (OA) is a degenerative joint condition that is persistent. OA affects millions of people throughout the world. Both people and society are heavily economically burdened by osteoarthritis. There is currently no medication that can structurally alter the OA processes or stop the disease from progressing. Stem cells have the potential to revolutionize medicine due to their capacity to differentiate into chondrocytes, capacity to heal tissues and organs including osteoarthritic joints, and immunomodulatory capabilities. Therefore, the goal of the current investigation was to determine how bone marrow-derived mesenchymal stem cells (BM-MSCs) and chondrogenic differentiated mesenchymal stem cells (CD-MSCs) affected the treatment of OA in rats with monosodium iodoacetate (MIA)-induced osteoarthritis.
Male Wistar rats were injected three times with MIA (1 mg)/100 µL isotonic saline to induce osteoarthritis in the ankle joint of the right hind leg. Following the MIA injection, the osteoarthritic rats were given weekly treatments of 1 × 10 BM-MSCs and CD-MSCs into the tail vein for three weeks.
The obtained results showed that in osteoarthritic rats, BM-MSCs and CD-MSCs dramatically decreased ankle diameter measurements, decreased oxidized glutathione (GSSG) level, and boosted glutathione peroxidase (GPx) and glutathione reductase (GR) activities. Additionally, in rats with MIA-induced OA, BM-MSCs and CD-MSCs dramatically boosted interleukin-10 (IL-10) serum levels while considerably decreasing serum anticitrullinated protein antibodies (ACPA), tumour necrosis factor-α (TNF-α), and interleukin-17 (IL-17) levels as well as ankle transforming growth factor-β1 (TGF-β1) expression. Analysis of histology, immunohistochemistry, and western blots in osteoarthritic joints showed that cartilage breakdown and joint inflammation gradually decreased over time.
It is possible to conclude from these results that BM-MSCs and CD-MSCs have anti-arthritic potential in MIA-induced OA, which may be mediated inhibitory effects on oxidative stress, MMPs and inflammation through suppressing the NF-κB pathway. In osteoarthritis, using CD-MSCs as a treatment is more beneficial therapeutically than using BM-MSCs.
骨关节炎(OA)是一种持续性的退行性关节疾病。OA影响着全球数百万人。骨关节炎给个人和社会都带来了沉重的经济负担。目前尚无药物能够在结构上改变OA进程或阻止疾病进展。干细胞因其能够分化为软骨细胞、修复包括骨关节炎关节在内的组织和器官以及具有免疫调节能力,而具有变革医学的潜力。因此,本研究的目的是确定骨髓间充质干细胞(BM-MSCs)和成软骨分化间充质干细胞(CD-MSCs)如何影响碘乙酸钠(MIA)诱导的骨关节炎大鼠的OA治疗。
雄性Wistar大鼠右后肢踝关节注射三次MIA(1mg)/100μL等渗盐水以诱导骨关节炎。MIA注射后,对骨关节炎大鼠每周经尾静脉注射1×10的BM-MSCs和CD-MSCs,共三周。
所得结果表明,在骨关节炎大鼠中,BM-MSCs和CD-MSCs显著减小了踝关节直径测量值,降低了氧化型谷胱甘肽(GSSG)水平,并提高了谷胱甘肽过氧化物酶(GPx)和谷胱甘肽还原酶(GR)的活性。此外,在MIA诱导的OA大鼠中,BM-MSCs和CD-MSCs显著提高了白细胞介素10(IL-10)的血清水平,同时显著降低了血清抗瓜氨酸化蛋白抗体(ACPA)、肿瘤坏死因子-α(TNF-α)和白细胞介素17(IL-17)水平以及踝关节转化生长因子-β1(TGF-β1)的表达。对骨关节炎关节的组织学、免疫组织化学和蛋白质免疫印迹分析表明,随着时间的推移,软骨破坏和关节炎症逐渐减轻。
从这些结果可以得出结论,BM-MSCs和CD-MSCs在MIA诱导的OA中具有抗关节炎潜力,这可能是通过抑制NF-κB途径对氧化应激、基质金属蛋白酶和炎症产生抑制作用来介导的。在骨关节炎中,使用CD-MSCs作为治疗方法比使用BM-MSCs在治疗上更有益。